In 2022, no quality-of-life indicator goal was met for people with diagnosed HIV aged 50 and older. If recent trends continue, 2025 goals for this group are unlikely to be met.
On June 27, 2024, the Advisory Committee on Immunization Practices recommended 21-valent pneumococcal conjugate vaccine (PCV21) as an option for adults 19 and older who are currently recommended to receive a dose of pneumococcal conjugate vaccine.
Health care providers who provide care for American Indian and Alaska Native infants should consider using DTaP-IPV-Hib-HepB as an option for the primary series at ages 2, 4, and 6 months; this product should not be used for booster doses.
